Focus-X Therapeutics
Sammamish · Founded 2020
About Focus-X Therapeutics
Focus-X Therapeutics is a preclinical-stage biotechnology company focused on the radiopharmaceutical pipeline. They focus on unmet needs in cancer diagnosis and therapy by applying our theragnostic approach to solid tumors with a very low five-year survival rate. It brings its proprietary radioligand therapy (RLT) to precisely deliver alpha or beta emitters to break down cancer cell DNA.
Company Facts
- Founded: 2020
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $1.5M
- Funding stage: M&A
- Last round: Series Unknown (Jan 2022)
- Website: https://www.focus-xtx.com/
Industries & Categories
Biotechnology
Social Profiles
Canonical: https://fsome.com/organization/focus-x-therapeutics-26103 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.